Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.

International journal of molecular sciences - 18 Apr 2020

Kim Hyera, Lee Su Jin, Lee In Kyoung, Min Suejean C, Sung Hyun Hwan, Jeong Byong Chang, Lee Jeeyun, Park Se Hoon

Abstract excerpt

Despite comprehensive genomic analyses, no targeted therapies are approved for bladder cancer. Here, we investigate whether a single and combination therapy with targeted agents exert antitumor effects on bladder cancer cells through genomic alterations using a three-dimensional (3D) high-throughput screening (HTS) platform. Seven human bladder cancer cell lines were used to screen 24 targeted agents. The effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Morpholines

Share to Pyrroles

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 32325639
DOI: 10.3390/ijms21082825
PMCID: PMC7215775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.PMID 32325639Read ↗

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine ResponseSemantic proximity Read ↗

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Semantic proximity Read ↗

Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.Semantic proximity Read ↗

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read ↗

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitorsSemantic proximity Read ↗

Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Semantic proximity Read ↗

Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic CancerSemantic proximity Read ↗

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.Semantic proximity Read ↗

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read ↗

Synergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.